Medicare drug coverage

Synjardy: 2027 Medicare Part D coverage

2,812 of 5,495 Part D plans (51%) list Synjardy on their 2027 formulary, the plan's list of covered drugs (down 15 points from 2026). 94% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Synjardy is number 130 by total Medicare Part D spending in 2024 ($321 million). Plans that list it most often put it on tier 3 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 9 RxNorm products for this name.

Synjardy Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it3,626 (66%)2,812 (51%)-15 points
Prior authorization (of plans that list it)0 (0%)40 (1%)+1 point
Step therapy (of plans that list it)23 (1%)0 (0%)-1 point
Quantity limit (of plans that list it)3,485 (96%)2,646 (94%)-2 points
Any of the three (of plans that list it)3,485 (96%)2,646 (94%)-2 points
Not listed or restricted (of all plans)5,377 (97%)5,329 (97%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

Formulary tier

Synjardy formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1138 (4%)59 (2%)
Tier 252 (1%)245 (9%)
Tier 33,386 (93%)2,494 (89%)
Tier 427 (1%)6 (0%)
Tier 623 (1%)8 (0%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 37 of them (1%) added prior authorization, step therapy, or a quantity limit for Synjardy, and 932 stopped listing it.

Synjardy: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 2027932 (21%)
Listed it in 2027, not in 2026330 (8%)
Moved it to a higher tier21 (0%)
Added prior authorization34 (1%)
Added step therapy0 (0%)
Added a quantity limit3 (0%)
Added at least one of the three37 (1%)
Removed at least one of the three39 (1%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Synjardy off the formulary or list it with prior authorization, step therapy, or a quantity limit. 28 states tie for the highest share, 100%; Massachusetts ranks last at 52%. The table breaks ties on the prior authorization or step therapy share.

States from most to least restrictive for Synjardy, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Alaska9100%0%no change
2Alabama115100%0%no change
3Arkansas86100%0%no change
4California397100%0%no change
5Colorado106100%0%no change
6Connecticut54100%0%+4 points
7District of Columbia21100%0%no change
8Idaho45100%0%no change
9Kansas84100%0%no change
10Kentucky123100%0%+1 point
11Maryland49100%0%+5 points
12Maine52100%0%no change
13Mississippi105100%0%no change
14Montana27100%0%no change
15New Hampshire25100%0%no change
16New Mexico68100%0%no change
17Nevada100100%0%+5 points
18Ohio173100%0%no change
19Oklahoma81100%0%no change
20Oregon92100%0%+1 point
21Rhode Island29100%0%no change
22Tennessee157100%0%no change
23Utah53100%0%no change
24Virginia145100%0%no change
25Vermont14100%0%no change
26Washington114100%0%no change
27West Virginia70100%0%no change
28Wyoming13100%0%no change
29Illinois13399%0%no change
30Louisiana12699%0%-1 point
31Texas41299%0%no change
32Michigan18399%22%-1 point
33Missouri17198%0%no change
34Pennsylvania32498%0%-1 point
35Georgia15198%0%-2 points
36Hawaii5098%0%+2 points
37Indiana14098%0%no change
38New York21597%0%no change
39Florida54997%0%no change
40Delaware4395%0%-5 points
41Arizona14894%0%-2 points
42Nebraska5192%0%-1 point
43New Jersey7491%0%-9 points
44South Carolina9190%0%-2 points
45North Carolina17790%0%-6 points
46Iowa6488%0%no change
47Minnesota6387%0%-6 points
48South Dakota3087%0%no change
49Wisconsin9786%0%no change
50North Dakota2685%0%no change
51Massachusetts9252%0%-10 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Synjardy off or restrict it.

Synjardy coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
BrightSpring Health Services, Inc.2100%100%100%no change0
Community Health Group2100%100%100%no change0
Community Health Plan of Washington2100%100%100%no change0
Denver Health and Hospital Authority2100%100%100%no change0
Elevance Health, Inc. & BCBSMA & BCBSRI & BCBSVT20%none list it100%no change0
Elite Health Systems, Inc.2100%100%100%no change0
Group Health Cooperative of Eau Claire2100%100%100%no change0
Hamaspik of Rockland County, Inc.2100%100%100%no change0
ISNP Holdings, LLC20%none list it100%no change0
Kansas Superior Select20%none list it100%no change0
Missouri Healthcare Advisors, LLC20%none list it100%no change0
MultiCare Health Systems20%none list it100%new in 20270
NEIGHBORHOOD HEALTH PLAN OF RHODE ISLAND20%none list it100%no change0
PrimeWest Rural MN Health Care Access Initiative2100%100%100%no change0
Regency ISNP Holdings LLC2100%100%100%no change0
Select Founders, LLC2100%100%100%no change0
Sentara Health Care (SHC)20%none list it100%no change0
South Country Health Alliance2100%0%0%-100 points0
The Regents of the University of California2100%100%100%no change0
Troy Holdings, Inc.2100%100%100%no change0
Associated Care Ventures, Inc.30%none list it100%no change0
Aultman Health Foundation3100%100%100%no change0
Banner Health3100%100%100%no change0
Bexar County Hospital District30%none list it100%no change0
Blue Cross Blue Shield of Nebraska3100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.